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Abstract There is great heterogeneity of immunity among pa-
tients with cryptococcosis, and severe immunodeficiency can
lead to negative clinical outcomes. Underlying disease is a poor
surrogate for immune status and inferior in predicting an indi-
vidual’s prognosis. This study was intended to determine
whether T-lymphocyte subgroups would be more suitable indi-
cators regarding the severity of infection and clinical outcomes
of such patients. We retrieved clinical data on 101 patients with
cryptococcosis and compared the validity of multiple parame-
ters (underlying disease and T-lymphocyte subgroups) in
predicting the severity of infection and clinical outcome in these
patients. For patients with CD4+ T-lymphocyte counts lower
than 400/μL, the odds ratio of disseminated cryptococcosis
was 23.3 (P = 0.005). There was a moderate negative correla-
tion between CD4+ T-cell count and Apache II score (−0.609,
P < 0.001). Mortality among patients with low levels of CD4+
T lymphocytes was significantly higher than among those with
normal levels (23.8% vs 5.3%, P = 0.016). However, the differ-
ence was not significant if the patients were grouped by under-
lying disease (P = 0.067). The CD4+ T-lymphocyte count in
peripheral blood is a simple and more accurate biomarker for
predicting severity of infection and clinical outcome in patients
with cryptococcosis.
Introduction
Cryptococcosis is a potentially life-threatening systemic my-
cosis [1]. Inhalation of Cryptococcus spores is the main route
of infection; such spores may remain isolated in the lungs or
spread to other organs, depending on the host’s immune status
[2]. The central nervous system (CNS) is considered to be the
most vulnerable organ involved in this process. Disseminated
disease, especially CNS involvement, often points to a need
for timely, aggressive treatment [3] and a much higher mor-
tality without it [4]. Thus, the risk factors for dissemination
(i.e., the host’s immune status or underlying diseases) are al-
ways the top concerns of clinicians seeking to manage this
infection.
With their significantly heterogeneous levels of immunity,
those susceptible to infection with Cryptococcus include pa-
tients with human immunodeficiency virus (HIV)/adult im-
munodeficiency syndrome (AIDS), organ transplant recipi-
ents [5], and patients with sarcoidosis [6], liver failure [7],
leukemia [8], or diabetes mellitus [9] as well as those receiv-
ing aggressive drug therapy [10]. Cryptococcosis may, in fact,
arise even in patients with no underlying disease [11, 12]. In
other words, these patients may have various degrees of im-
mune deficiency and risk for dissemination. Up to now, clin-
ical guidelines have recommended that clinicians evaluate
their patients’ underlying diseases and take the findings as
one of the main classification criteria for planning a therapeu-
tic regimen. But we found this approach inadequate. In short,
it is imperative to find other parameters for evaluating pa-
tients’ immune status and predicting disease severity and clin-
ical outcome.
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Many studies suggest that cell-mediated immunity, espe-
cially in terms of T lymphocytes, plays an important role in
countering cryptococcal infection [13–15]. For example,
AIDS patients have been characterized by CD4+ T-cell deple-
tion and inversion of the CD4+/CD8+ ratio [16]. One recent
study from Germany suggested that routine screening for
cryptococcosis by testing with cryptococcal antigen (CRAG)
is highly recommended for AIDS patients with CD4+ T-cell
counts ≤200/μL [17]. Another example involves the use of
rabbit anti-thymocyte globulin and alemtuzumab, which have
been given to organ transplant patients to counteract acute
rejection; however, this treatment can induce a substantial
decline in the number of CD4+ T cells and thus increase the
risk of cryptococcal infection [18]. Idiopathic CD4+ T
lymphocytopenia has also been reported to be an important
predisposing factor for cryptococcosis [19, 20]. By the recruit-
ment of granulocytes and macrophages in the lungs and the
production of IL-12, TNF-α, and IFN-γ, CD4+ T cells have
been shown to protect mice against cryptococcal infection
[15]. All these examples show that T lymphocyte subgroups
play an important role in the pathogenesis of cryptococcosis.
Clinicians need a simple, straightforward indicator to de-
termine an individual’s immune status and thus to predict the
risk of disseminated cryptococcal disease and its potential
severity, also keeping in mind other possible underlying dis-
eases. T-lymphocyte subgroups constitute quantitative param-
eters; their numbers can readily be determined in routine clin-
ical practice. With this in mind, we launched a retrospective
study to compare the predictive role of underlying diseases
and T-lymphocyte subgroups for patients with cryptococcosis
and to find out which parameter would have the greatest pre-
dictive power.
Methods and materials
We retrieved the clinical data of adult cryptococcosis patients
in Jingling Hospital, and the Second Hospital of Nanjing,
Nanjing, China. The diagnosis of cryptococcosis was con-
firmed either by histopathological examination of tissue sam-
ples (obtained by percutaneous lung biopsy, surgical resec-
tion, bronchoscope biopsy) or by positive staining/culture re-
sults from cerebrospinal fluid and/or blood. Clinical diagnoses
were made on the basis of typical clinical manifestations and
the cryptococcal antigen test. We ruled out those suspected
cases that did not fulfill our diagnostic criteria as well as cases
that did not include data on the peripheral blood T-lymphocyte
subgroups at the time of diagnosis.
According to the classification criteria of the clinical prac-
tice guidelines for the management of cryptococcal disease
published by the Infectious Disease Society of America in
2010, patients with cryptococcosis fall into several groups:
the AIDS group, organ transplantation recipient (OTR) group,
andNHNT (non-HIV-infected and non-transplant host) group.
Patients with HIV infection and those who have received solid
organ transplants were allocated to the AIDS and OTR
groups, respectively. Since the heterogeneity of the NHNT
group is quite large, this group was divided again [21] into
the NHNT-1 group (where the patient suffered from one or
more diseases that can cause mild or moderate immune defi-
ciency and increase the risk of infection, such as autoimmune
disease, diabetes mellitus, hematological disease, and so on)
and the NHNT-2 group (comprising patients with no detect-
able immunological defects or underlying diseases).
Flow cytometry performed by professional technicians was
used to analyze T-lymphocyte subgroups among our patients
at admission. In addition, the findings on chest CT were de-
scribed by two radiologists at Jinling Hospital.
Apache II scores and acute physical and chronic health
evaluations were widely applied to assess the severity of dis-
ease [12, 22]. Integral scores ranged from 0 to 71, a higher
score indicating a more severe condition and poorer progno-
sis. This score was determined according to the patient’s con-
dition prior to antifungal therapy. Survival at the conclusion of
our study (follow-up of at least 3 months for each patient [4])
constituted the clinical outcome. All data were acquired from
medical records or telephone follow-up.
Statistical analysis
Data were described as means (standard deviation) and per-
centages. One-way analysis of variance, t-tests, and chi-square
tests were used in comparing the baseline characteristics.
Because of the heterogeneity of our data, T-lymphocyte sub-
groups were expressed in terms of the median; the Kruskal-
Wallis H test was applied in comparing the four groups; sub-
sequently the Nemenyi test was used to make paired compar-
isons. The cutoff value of parameters was determined by re-
ceiver operating characteristic (ROC) curves and Youden’s
index. The association was assessed by Spearman’s correla-
tion analysis. The chi-square test was used in comparing
groups. Significance was defined as P <0.05 with two-sided
analysis. We analyzed all data with SPSS software, version
17.0.
Results
Between January 2009 and July 2015, a total of 106 proven
cases of cryptococcosis were collected, including an AIDS
group (n = 30), an OTR group (n = 15), a NHNT-1 (n = 32)
group, and a NHNT-2 (n = 29) group. The AIDS patients were
characterized by a substantial decrease in the number of CD4+
T cells, and OTR patients had to be treated with immunosup-
pressants, so their T-lymphocyte counts were also low. All T-
lymphocyte counts were routinely evaluated in these patients.
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Two NHNT-1 cases and three NHNT-2 cases had not been
studied for T-lymphocyte subgroups. In sum, 101 cases
met all our criteria and were therefore included in this study.
There were 73 male and 28 female patients from 16 to 78
(41.4 ± 13.6) years of age. Of the total, 26 patients had no
comorbidity (NHNT-2 group). The other 75 patients were
assigned to the AIDS group (n = 30), OTR group (n = 15), or
NHNT-1 group (n = 30). The demographic data for each
group are listed in Table 1.
All 15 patients in the OTR group were kidney transplant
recipients. The NHNT-1 patients suffered from various un-
derlying diseases, including lupus nephritis, nephritic syn-
drome, lymphoma, and so on. NHNT-2 patients had no
detectable diseases that could compromise their immune
systems. Except for the underlying diseases, the baseline
characteristics of each group were comparable (P > 0.05)
(Table 1).
The definition of disseminated cryptococcosis includes the
involvement of CNS involvement, at least two noncontiguous
sites [17] or cryptococcemia [17]. Local cryptococcosis [17] is
defined as pulmonary cryptococcosis with or without pleural
effusion or as focal lymphadenopathy. Our study showed that
the proportions of disseminated disease in the AIDS, OTR,
NHNT-1, and NHNT-2 groups were 86.7%, 80%, 50%, and
11.5%, respectively, and the difference between groups
reached statistical significance (P < 0.001) (Table 1). It is note-
worthy that the dissemination rate in the NHNT-1 group was
much higher than we had expected. One reason may be that
most of these patients had been receiving aggressive treatment
with immunosuppressants before the onset of cryptococcosis.
T-lymphocyte subgroups
The median of CD4+ T cell counts in the AIDS group was
much lower than that in the OTR, NHNT-1, or NHNT-2
groups, with statistical significance (median, 18 vs 270, 214,
and 663; P < .001). The median of CD4+ T-cell counts in the
NHNT-2 group was greater than that in the OTR group (me-
dian, 663 vs 270; P < .05) and NHNT-1 group (median 663 vs
214; P < .005) (Fig. 1a).
CD8+ T-cell counts in the OTR and NHNT-1 groups were
lower than those in the AIDS and NHNT-2 groups (median,
215, 247 vs 432.5, 477.5; P = 0.004) (Fig. 1b). The median of
CD3+ T-cell counts in the NHNT-2 group was much higher
than that in the AIDS, OTR, and NHNT-1 groups, with statis-
tical significance (1213.5 vs 471.5, 528, 461.5; P < 0.001)
(Fig. 1c).
CD4+/CD8+ ratio in the AIDS group was lower than OTR,
NHNT-1 and NHNT-2 groups with statistical significance
(median, 0.04 vs 1.39, 0.72, 1.52; P < 0.001). The difference
in CD4+/CD8+ ratio between the NHNT-1 group and the
NHNT-2 group reached statistical significance (median, 0.72
vs 1.52; P < 0.05) (Fig. 1d).
Table 1 Demographic data on
101 patients with cryptococcosis,
2009–2015
Characteristic AIDS, n = 30 OTR, n = 15 NHNT-1, n = 30 NHNT-2, n = 26 P value
Male 26(86.7%) 11(73.3%) 17(56.7%) 19 (73.1%) 0.074
Age (years) 37.8 ± 11.5 42.8 ± 12.9 42.3 ± 17.4 43.9 ± 10.4 0.219
Underlying disease
SOT (kidney) None 15 None None
Renal disease None 15 12(40%) None
AID None None 11(36.7%) None
Hemopathy None None 5(16.7%) None
Diabetes mellitus None 3(20%) 6(20%) None
ILC None None 4(13.3%) None
Liver dysfunction None None 1(3.3%) None
Site of infection
Disseminated 26(86.7%) 12(80%) 15(50%) 3(11.5%) <0.001
Local 4(13.3%) 3(20%) 15(50%) 23(88.5%)
AID autoimmune disease, AIDS acquired immunodeficiency syndrome, ICL idiopathic CD4+ lymphopenia,
NHNT non-HIV-infected and non-transplant host,OTR organ transplantation recipient, SOT solid organ transplant
Renal disease in the NHNT-1 group included lupus nephritis (n = 8), nephritic syndrome (n = 2), podocytopathy
(n = 1) and allergic tubule-interstitial nephritis (n = 1).
Autoimmune disease included SLE (n = 8), pemphigoid (n = 1) and rheumatoid arthritis (n = 2).
Hemopathy included malignant lymphoma (n = 2), myelodysplastic syndromes (n = 2) and allergic purpura (n =
1).
The data was described in percentage or mean (standard deviation). One-way analysis of variance and chi-square
test were used in comparison between groups.
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The predictive value of these parameters in assessing
the risk of disseminated cryptococcosis
First, our study sought to determine whether the parameters of
cell-mediated immunity are more accurate than the underlying
disease burden in predicting the incidence of dissemination.
Second, we sought to discover which of the T-lymphocyte
subgroups would be the most sensitive predictor. We applied
the ROC curves and Youden’s index to determine the cutoff
value of T-lymphocyte subgroups. Then we found the cutoff
value of CD4+ T cell counts of 400/uL for predicting dissem-
ination; the sensitivity and specificity were 80% and 98.2%.
The area under concentration-time curve (AUC) was 0.903
and the 95% confidence interval ranged from 0.835 to 0.970
(These data are shown in ESM_Figure2A). Similarly, suppos-
ing 617/μL to be the cutoff value of CD3+ T-cell counts, the
sensitivity and specificity to predict the dissemination were
86.7% and 82.1%, respectively. The AUC was 0.890 and the
95% confidence interval ranged from 0.823 to 0.957 (the data
are shown in ESM_Figure2B). Because of the poor result of
AUC in CD8+ T cells (0.732) and the CD4+/CD8+ ratio
(0.777), the normal lower limit (242/μL, 0.90) was chosen
as the cutoff value.
Thenwe reclassified the patients according to the following
criteria: (1) Underlying disease: the patients with AIDS/OTR
(n = 45) were classified in the group with severe underlying
disease (group A) and the remainders (n = 56) in the group
without severe underlying disease (group B). (2) CD4+/
CD8+ ratio: the patients with a CD4+/CD8+ ratio below the
normal lower limit (n = 59) were classified in group C, and the
others (n =42) in group D. (3) CD8+ T-lymphocyte count: the
patients with CD8+ T-lymphocyte counts lower than 242/μL
(n = 28) were classified in group E and the others (n = 73) in
group F. (4) CD3+ T-lymphocyte count: the patients with
CD3+ T-lymphocyte counts below 617/μL (n = 52) were clas-
sified in group G and the remaining patients (n = 49) in group
H. (5) CD4+ T-lymphocyte count: the patients with CD4+ T-
lymphocyte counts below 400/μL (n = 63) made up group I,
while the normal (n = 38) patients were classified in group J.
The differences between groups in terms of most baseline
characteristics according to different classification criteria
were comparable (P > 0.05) (these data are shown in
ESM_Table).
On further study, we evaluated the predictive role of
underlying diseases and T-cell subgroups regarding dis-
ease severity and prognosis according to the various clas-
sifications. First, we screened the risk factors that could
best predict the general distribution of lesions by single-
factor logistic regression analysis. Our study showed that
both underlying disease and the parameter of T-
lymphocyte subgroups had an effective role in predicting
the risk of disseminated cryptococcosis. However, we did
not find a close link between male gender/age and inci-
dence of dissemination (Table 2). In consideration of in-
teractions, multivariable logistic regression analysis was
applied, and our data suggested that the CD4+ T-
lymphocyte count was the most sensitive predictor; the
odds ratio was 23.3 (95% CI: 2.6–209.7; P = .005), while
the other parameter did not reach statistical significance
(P > 0.05) (Table 3). With regard to influence on the dis-
tribution of pulmonary lesions, the proportion of unilateral
lung lesion in groups A, C, E, G, and I were 66.7%, 61.5%,
42.9%, 53.6%, and 55.6% vs 44.1%, 58.6%, 64.8%, 65%,
and 65.6% in groups B, D, F, group H, and J, respectively.
There was no statistical significance in these comparisons





















































































































Fig. 1 T-lymphocyte counts of
101 patients with cryptococcosis,
2009–2015; (a) CD4+, (b) CD8+,
(c) CD3+, and (d) CD4+/CD8+
ratio. The median was used to
describe the data. The Kruskal-
Wallis H test was applied in
comparing the four groups;
subsequently, the Nemenyi test
was used in paired comparisons
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The role in assessing the disease severity and mortality
A moderate negative correlation was found between the
CD4+ T-cell count and Apache II score. The correlation
coefficient was −0.609 (P < 0.001), which was higher than
that of CD3+ T-cell count (−0.572), underlying disease
(−0.471), CD8+ T-cell count (−0.384) and CD4+/CD8+ ra-
tio, respectively (−0.276) (P < 0.05) (Table 5). Our study
further evaluated the predictive role of underlying disease
and T-lymphocyte subgroups with regard to mortality. The
mortality of the patients with decreased CD4+ T lympho-
cytes was 23.8%, which was higher than that (5.3%) of the
patients with normal CD4+ T lymphocyte (P = 0.016). The
mortality of cryptococcosis patients with severe underlying
diseases was slightly higher than that in the patients with
relatively mild diseases, but the difference did not reach
statistical significance (24.4% vs 10.7%; P = 0.067).
There was also no statistical significance among the other
parameters (P > 0.05) (Table 6).
Discussion
As far as we know, data on T-lymphocyte subgroups in pa-
tients with cryptococcosis have been derived mainly from
AIDS patients, whereas studies related to non-AIDS patients
have been rare. Therefore our study reviewed the data on T-
lymphocyte subgroups in patients with cryptococcosis from
eastern China and considered the role of cell immunity in
assessing disease severity and prognosis.
We observed consistent results in AIDS patients, whose
CD4+ T lymphocytes were lower than 50/μL in 83.3% cases
and lower than 200/μL in 96.7% cases. Previous research also
found CD4+ T-lymphocyte counts lower than 50/μL in 78%
and 200/μL in 97% of AIDS patients suffering from crypto-
coccosis [23]. Inversion of the CD4+/CD8+ ratio was found in
all the AIDS patients in our study [16]. Furthermore, a clear-
cut result was derived from the NHNT-2 patients in that most
of their CD4+ and CD8+ T-cell counts were normal, but the
CD4+/CD8+ ratio was decreased in some patients.
Table 2 The results of predictors
in assessing the risk of
disseminated lesions among 101
patients with cryptococcosis,
2009–2015


















































Single-factor logistic regression analysis was used to screen the predictors in assessing the risk of dissemination
cryptococcosis
Table 3 The results of predictors
in assessing the risk of
disseminated lesion among 101
patients with cryptococcosis,
2009–2015




































Multivariable logistic regression analysis was applied in predicting the risk of disseminated cryptococcosis
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Other than AIDS and NHNT-2 patients, a heterogeneous
result was obtained in OTR and NHNT-1 patients. The
number of CD4+ T-lymphocytes decreased in 80% and
CD8+ T cells decreased in 53.3% of the OTR patients,
but their CD4+/CD8+ ratios generally remained normal.
Some patients in the NHNT-1 group resembled those in
the AIDS or OTR groups and others were similar to pa-
tients in the NHNT-2 group. Overall we found that
cryptococcosis patients exhibit an obvious heterogeneity
of immune status.
The levels of CD8+ T cells were normal or increased in the
AIDS patients, whereas they were sharply decreased in the
OTR patients and those receiving large doses of immunosup-
pressants. It should be emphasized that a decrease in the CD8+
T-cell count can lead to a normal CD4+/CD8+ ratio in patients
with low numbers of CD4+ lymphocytes [24]. In short, our
Table 5 Relation between the
classification standards and the
scores of APACHE II
Characteristic APACHE II score Correlation coefficient P value
≤5 6 ∼ 10 ≥11
Underlying disease
Group A (n = 45) 6 16 23 −0.471 <0.001
Group B (n = 56) 38 5 13
CD4+/CD8+ ratio
Group C (n = 59) 16 20 23 −0.276 0.006
Group D (n = 42) 28 1 13
CD8+ T cell count
Group E (n = 28) 3 9 16 −0.384 <0.001
Group F (n = 73) 41 12 20
CD3+ T cell count
Group G (n = 52) 6 19 27 −0.572 <0.001
Group H (n = 49) 38 2 9
CD4+ T-cell count
Group I (n = 63) 11 20 32 −0.609 <0.001
Group J (n = 38) 33 1 4
The Spearman correlation analysis was used in comparison







Group A (n = 24) 16(66.7%) 8(33.3%) 0.428
Group B (n = 44) 25(44.1%) 19(55.9%)
CD4+/CD8+ ratio
Group C (n = 39) 24(61.5%) 15(38.5%) 0.808
Group D (n = 29) 17(58.6%) 12(41.4%)
CD8+ T cell count
Group E (n = 14) 6(42.9%) 8(57.1%) 0.135
Group F (n = 54) 35(64.8%) 19(35.2%)
CD3+ T cell count
Group G (n = 28) 15(53.6%) 13(46.4%) 0.343
Group H (n = 40) 26(65%) 14(35%)
CD4+ T cell count
Group I (n = 36) 20(55.6%) 16(44.4%) 0.397
Group J (n = 32) 21(65.6%) 11(34.4%)
Chi-square test was used to compare the difference in proportion of bi-
lateral lung lesion between two groups
Table 6 Mortality and classification standards
Characteristic Deatha, n = 17 Survival, n = 84 P value
Underlying disease
Group A (n = 45) 11(24.4%) 34(75.6%) 0.067
Group B (n = 56) 6(10.7%) 50(89.3%)
CD4+/CD8+ ratio
Group C (n = 59) 12(20.3%) 47(79.7%) 0.264
Group D (n = 42) 5(11.9%) 37(88.1%)
CD8+ T-cell count
Group E (n = 28) 6(21.4%) 22(78.6%) 0.640
Group F (n = 73) 11(15.1%) 62(84.9%)
CD3+ T-cell count
Group G (n = 52) 10(19.2%) 42(80.8%) 0.507
Group H (n = 49) 7(14.3%) 42(85.7%)
CD4+ T-cell count
Group I (n = 63) 15(23.8%) 48(76.2%) 0.016
Group J (n = 38) 2(5.3%) 36(94.7%)
Chi-square test was used to compare the difference in mortality of cryp-
tococcosis between two groups
a Attributed death
Eur J Clin Microbiol Infect Dis
study suggests that the value of CD4+/CD8+ ratios, CD8+ T-
cell counts, or CD3+ T-cell counts is relatively limited in de-
termining the immune status of patients with cryptococcosis.
In a word, the CD4+ T-cell count was felt to be the most
valuable parameter in evaluating the cell immunity of the pa-
tients in our study.
Disseminated cryptococcosis was tightly linked with the
immune status of cryptococcosis patients. Granuloma was
among the most common pathological result of pulmonary
lesions in cryptococcosis patients; this was mainly induced
by CD4+ T-cell immunity [25]. Integrated granuloma may
prevent the dissemination of cryptococcal disease. Recent
studies show that Th1/Th17 lymphocytes, which are CD4+
T-cell subgroups, may prevent dissemination [26]. The
CD4+ T-cell count was sharply decreased (median, 82/μL;
range 7–292/μL) in 53 patients with idiopathic CD4+ T
lymphocytopenia and cryptococcosis [19]. There was CNS
involvement in 75.4% of these patients [19]. CD4+ T-cell
counts were also decreased in eight patients with systemic
lupus erythematosus who also suffered from cryptococcal
meningitis (mean ± SD, 113.2 ± 59.2/μL) [27]. One AIDS
study revealed that CD4+ T-cell counts in patients with local
cryptococcosis were higher than in those with disseminated
cryptococcosis [28]. Our study confirmed that as opposed to
underlying disease, the CD4+ T-cell count is a more effective
predictor of disseminated cryptococcosis.
Recent studies have reported that the proportions of patchy
shadow, consolidation, and cavities in immunocompromised
patients were higher than in immunocompetent patients [21,
29, 30]; therefore, we speculated that imaging of the chest in
our immunocompromised patients might be more severe than
it was in those who were immunocompetent. However, we
found that neither underlying disease nor T-lymphocyte sub-
groups were good predictors for the distribution of lung le-
sions. Since inhaled cryptococcal spores are the main source
of infection, we assumed that their presence might be more
important as an indicator of lung lesions.
Joseph et al. discovered that the Cryptococcus-specific
CD4+ memory T-cell response to Cryptococcus is closely cor-
related with clinical severity and outcome in AIDS patients
with cryptococcal meningitis [31]. Our study suggests that the
total CD4+ T-cell count is also effective in assessing disease
severity and mortality among patients either with or without
HIV infection.
Inevitably, our study has some limitations. First, it is a
retrospective study. Second, our study retrieved data from of
T-lymphocyte subgroups at only one time point and before
antifungal therapy. Dynamic changes in T-lymphocyte sub-
groups during the follow-up period were not clear. In a further
study, therefore, a prospective design and dynamic follow-up
of T-lymphocyte subgroups will be needed.
In conclusion, the CD4+ T-cell count is an effective indica-
tor of a patient’s immune status and provides a more accurate
estimate of disease severity and prognosis in cases of crypto-
coccal infection. In other words, a count of CD4+ Tcells in the
peripheral blood of each patient with cryptococcosis should be
done routinely. For those with low CD4+ T-cell counts, testing
for possible dissemination should proceed as promptly as
possible.
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